Antipsychotic drugs, neurotransmitters, and schizophrenia
- PMID: 23684
- DOI: 10.1176/ajp.135.2.165
Antipsychotic drugs, neurotransmitters, and schizophrenia
Abstract
Inhibition of central dopamine functions appears to be a common basic property of antipsychotic drugs. The mesolimbic and nigrostriatal portions of the dopaminergic system are probably the main targets for the mental and the extrapyramidal actions, respectively, of these drugs. The fact that dopaminergic hyperfunction induced by amphetamines or dopa may lead to a disturbance mimicking paranoid schizophrenia lends further support for a key role of dopamine in mental functions. Although a primary disturbance in dopamine function in schizophrenia cannot be ruled out, the intimate relationship between dopaminergic and other neuronal systems must be emphasized. The possible involvement of other amine, amino acid, or peptide transmitters in schizophrenia cannot be disregarded.
Similar articles
-
Does dopamine play a role in schizophrenia?Psychol Med. 1977 Nov;7(4):583-97. doi: 10.1017/s003329170000622x. Psychol Med. 1977. PMID: 22890
-
[Current theories on the role of dopamine in the mechanism of action of neuroleptic drugs].Psychiatr Pol. 1984 Jan-Feb;18(1):39-47. Psychiatr Pol. 1984. PMID: 6146150 Review. Polish. No abstract available.
-
Antipsychotic drugs and catecholamine synapses. Summary of the session.J Psychiatr Res. 1974;11:97-104. doi: 10.1016/0022-3956(74)90079-x. J Psychiatr Res. 1974. PMID: 4156797 No abstract available.
-
Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.Neuroscience. 1978;3(9):773-83. doi: 10.1016/0306-4522(78)90030-1. Neuroscience. 1978. PMID: 30919 Review. No abstract available.
-
Preferential effect of noncataleptogenic neuroleptics on mesolimbic dopaminergic function.Adv Biochem Psychopharmacol. 1977;16:607-11. Adv Biochem Psychopharmacol. 1977. PMID: 18902 No abstract available.
Cited by
-
Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.Psychopharmacology (Berl). 2008 Feb;196(3):417-29. doi: 10.1007/s00213-007-0973-y. Epub 2007 Oct 17. Psychopharmacology (Berl). 2008. PMID: 17940749
-
Sexual behavior of the male schizophrenic: the impact of illness and medications.Arch Sex Behav. 1981 Oct;10(5):421-42. doi: 10.1007/BF01541435. Arch Sex Behav. 1981. PMID: 6119066 Review.
-
Pre- and postsynaptic dopaminergic activities of U-86170F.Naunyn Schmiedebergs Arch Pharmacol. 1991 Nov;344(5):509-13. doi: 10.1007/BF00170644. Naunyn Schmiedebergs Arch Pharmacol. 1991. PMID: 1687420
-
A biologic model to study the genetics of psychotic, mood, and anxiety disorders: the velocardiofacial syndrome.Curr Psychiatry Rep. 2006 Apr;8(2):90-5. doi: 10.1007/s11920-006-0004-4. Curr Psychiatry Rep. 2006. PMID: 16539882 Review.
-
Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.Clin Drug Investig. 2007;27(1):1-13. doi: 10.2165/00044011-200727010-00001. Clin Drug Investig. 2007. PMID: 17177576
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources